Unconfigured Ad

Established in 1998, Illumina began its journey into the field of genomics with the launch of its BeadArray technology for high-throughput genotyping of single nucleotide polymorphisms (SNPs). Through the key acquisition of sequencing company Solexa and the persistent development of their instruments, Illumina transformed itself into an international leader in sequencing technologies.

Illumina currently maintains a large majority of the sequencing market,...

In the Fall of 2022 Illumina announced their newest pair of flagship sequencers: the NovaSeq X and the NovaSeq X Plus. Their development was part of Illumina’s pursuit of lowering the cost of sequencing by dropping the price to approximately $200 per genome. The major differences between Illumina’s previous top sequencer (the NovaSeq 6000) and the NovaSeq X and X Plus are that the new devices have more affordable and updated reagents, faster run times, and the ability to process data directly...